Ethylcellulose Coated Tablets for GHB Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating a controlled release dosage form for high-dose, low molecular weight, and highly water-soluble drugs like gamma-hydroxybutyrate (GHB) is challenging due to rapid permeation through films and matrices, short circulating half-life, and hygroscopic nature, which complicates sustained drug delivery and requires frequent dosing.
Innovation Solution
Developing controlled release formulations as coated tablets with a functional coating that includes a controlled release core and an optional immediate release component, using ethylcellulose and pore formers to control drug release, maintaining therapeutic levels over a prolonged period while resisting dose dumping and alcohol-induced release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose water-soluble drugs are used in controlled release formulations, then therapeutic efficacy is improved, but drug release control becomes difficult due to rapid permeation through films and matrices
Solution Approach 1:
The patent utilizes porous matrices as the rate-controlling excipient to achieve controlled release of high-dose water-soluble drugs. The porous structure provides a controlled pathway for drug diffusion, preventing rapid permeation while maintaining therapeutic efficacy. The porosity allows water penetration for drug dissolution while restricting uncontrolled drug release through the matrix.
Solution Approach 2:
The formulation employs composite materials combining the water-soluble drug with hydrophobic rate-controlling excipients and pore-forming agents. This composite approach creates a balanced system where the hydrophobic matrix controls release rate while pore-forming agents create channels for controlled drug diffusion, resolving the contradiction between high dose requirements and release control.
2Reliability
If high-dose drugs are administered, then therapeutic efficacy is improved, but the amount of rate controlling excipients is constrained, affecting formulation capability
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by incorporating pore-forming agents that create a controlled porous network. This allows the formulation to accommodate high drug doses while maintaining adequate rate-controlling excipient content. The pore structure modifies the release kinetics without requiring excessive amounts of rate-controlling materials.
Solution Approach 2:
By using porous matrices with optimized porosity and pore size distribution, the formulation can achieve controlled release with high drug loading. The porous structure provides sufficient surface area and diffusion pathways, reducing the need for large amounts of rate-controlling excipients while maintaining formulation simplicity.
3Reliability
If high-solubility drugs are used, then bioavailability is improved, but zero-order release kinetics become difficult to achieve
Solution Approach 1:
The porous matrix creates a controlled diffusion environment where water penetrates through the pores, dissolves the high-solubility drug, and releases it at a controlled rate. The porous structure ensures that the drug release is not limited by dissolution rate but by diffusion through the porous matrix, enabling zero-order kinetics despite high drug solubility.
Solution Approach 2:
The porous matrix acts as an intermediary between the high-solubility drug and the external environment. It controls the water-drug interaction and drug release kinetics, transforming the rapid dissolution characteristic of high-solubility drugs into a controlled zero-order release profile through the porous structure.
4Reliability
If hygroscopic drugs are formulated, then drug stability is improved, but structural integrity of the dosage form deteriorates
Solution Approach 1:
The patent employs a coating film as a protective shell around the hygroscopic drug-containing core. This thin film barrier prevents excessive water absorption from the environment while allowing controlled drug release. The coating maintains structural integrity by restraining the hygroscopic drug from absorbing too much moisture, which would otherwise cause swelling and disintegration.
Solution Approach 2:
The formulation uses composite materials combining hygroscopic drug with hydrophobic excipients and coating materials. This composite structure creates a balanced system where the hydrophobic components protect the hygroscopic drug from excessive moisture uptake, maintaining both drug stability and dosage form structural integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations achieve a sustained release of GHB over 4 to 12 hours, reducing frequency of dosing, minimizing pulsatile plasma concentrations, and ensuring consistent delivery despite gastrointestinal variability, while preventing dose dumping and maintaining structural integrity.
Implementation Method 1
the functional coating that includes a controlled release core and an optional immediate release component, using ethylcellulose and pore formers to control drug release
Implementation Method 2
drugs that are administered at a high dose, drugs having a low molecular weight, and drugs with high water solubility make formulation of a controlled release dosage form challenging
Data Source
AI summary
Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.